There are 2867 resources available
LBA6 - Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)
Presenter: Sapna Patel
Session: Presidential Symposium II
Resources:
Abstract
Slides
Webcast
ESMO and Covid 19: The trials and tribulations
Presenter: Marina Garassino
Session: The enigma of public policy in oncology: ESMO at the forefront
Resources:
Slides
Webcast
Invited Discussant 903O, 1696O and 66O
Presenter: Federica Di Nicolantonio
Session: Proffered Paper session: Basic science & translational research
Resources:
Slides
Webcast
Dyspnea and cough
Presenter: David Hui
Session: Minimizing some of the most distressing cancer and cancer treatment related symptoms
Resources:
Slides
Webcast
527MO - Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): Defining benefit according to disease risk subgroups within the phase 3 ATHENA–MONO study
Presenter: Rebecca Kristeleit
Session: Mini Oral session 2: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
LBA7 - Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study
Presenter: Myriam Chalabi
Session: Presidential Symposium II
Resources:
Abstract
Slides
Webcast
Onco-policy in Asia: ESMO to the fore
Presenter: Ravindran Kanesvaran
Session: The enigma of public policy in oncology: ESMO at the forefront
Resources:
Slides
Webcast
Invited Discussant LBA4, LBA5, LBA6, LBA7 - The immunologist point of view
Presenter: Sherene Loi
Session: Presidential Symposium II
Resources:
Slides
Webcast
Discussion
Presenter: All Speakers
Session: Minimizing some of the most distressing cancer and cancer treatment related symptoms
Resources:
Slides
Webcast
528MO - Is re-introduction or continuation of PARP inhibitors after local therapy for oligo-metastatic progression in patients with relapsed ovarian cancer relevant?
Presenter: Gauduchon Thibault
Session: Mini Oral session 2: Gynaecological cancers
Resources:
Abstract
Slides
Webcast